This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

On Monday, earnings and a variety of news related to drug-eluting stents weren't enough to dislodge flat health indices.

Excluding items, Merck (MRK - Get Report) earned 75 cents a share in the latest quarter, beating the consensus of 69 cents a share. Net income, including items, rose to $1.53 billion in the third quarter from $940.6 million in the same period a year ago.

Merck lifted its 2007 profit outlook, saying it should earn $3.08 to $3.14 a share, before items are counted. Analysts are looking for $3.07, according to Thomson Financial. Shares rose $1.37, or 2.6%, to $54.49.

On the other hand, Schering-Plough (SGP) earned 28 cents a share (excluding acquisition-related items and an upfront R&D payment), on revenue of $2.8 million. Analysts surveyed by Thomson Financial were expecting 30 cents a share on revenue of $2.87 million. Shares fell $4.25, or 13%, to $28.44.

Merck and Schering-Plough are both components of the Amex pharmaceutical index, which was down 2.48, or 0.7%, to 341.24.

Away from earnings, stents -- the mesh tubes sometimes frosted with antibiotic coating used to prop open clogged arteries -- have seen a decline in sales, but not in clinical trials or news.

First Medtronic (MDT - Get Report) received the CE mark for the commercial sale of the Endeavor Resolute Drug-Eluting Coronary Stent in Europe and plans to launch the product outside the U.S. earlier than originally projected.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
THRX $11.99 7.73%
ABT $37.13 0.00%
JNJ $101.82 0.00%
MDT $73.40 0.00%
MRK $49.03 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs